This is a working overview of clinical endpoint, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-17 and is reviewed periodically as new material appears.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
The increasingly repressive policies of the partitioning powers led to resistance movements in partitioned Poland, and in 1830 Polish patriots staged the November Uprising. This revolt developed into a full-scale war with Russia, but the leadership was taken over by Polish conservatives who were reluctant to challenge the empire and hostile to broadening the independence movement's social base through measures such as land reform. Despite the significant resources mobilized, a series of errors by several successive chief commanders appointed by the insurgent Polish National Government led to the defeat of its forces by the Russian army in 1831. Congress Poland lost its constitution and military, but formally remained a separate administrative unit within the Russian Empire.
Plant Cultures: Chilli pepper botany, history and uses The Chile Pepper Institute of New Mexico State University Capsicums: Innovative Uses of an Ancient Crop Chilli: La especia del Nuevo Mundo (Article from Germán Octavio López Riquelme about biology, nutrition, culture and medical topics. In Spanish) The Hot Pepper List List of chili pepper varieties ordered by heat rating in Scoville Heat Units (SHU)
=== Life Expectancy After Starting Kidney Dialysis === Life expectancy after starting kidney dialysis for end-stage kidney disease (ESKD) varies significantly based on factors such as age, comorbidities, dialysis modality, and access to healthcare. Dialysis extends life compared to untreated ESKD but does not restore normal kidney function. Median survival is approximately 3–5 years, with 5-year survival rates around 35–42% for hemodialysis (HD) patients. Mortality is highest in the first year (15–20%), primarily from cardiovascular events or infections.
Sources: en.wikipedia.org
This was important for the introduction of new emergency acts: the grand coalition gave the ruling parties the two-thirds majority of votes required for their ratification. These controversial acts allowed basic constitutional rights such as freedom of movement to be limited in case of a state of emergency.
==== MeSH D12.776.624.664.700 – proto-oncogene proteins ==== MeSH D12.776.624.664.700.100 – cyclin d1 MeSH D12.776.624.664.700.110 – fibroblast growth factor 4 MeSH D12.776.624.664.700.112 – fibroblast growth factor 6 MeSH D12.776.624.664.700.114 – fms-like tyrosine kinase 3 MeSH D12.776.624.664.700.120 – receptor, fibroblast growth factor, type 3 MeSH D12.776.624.664.700.130 – muts homolog 2 protein MeSH D12.776.624.664.700.148 – myeloid-lymphoid leukemia protein MeSH D12.776.624.664.700.167 – proto-oncogene proteins c-abl MeSH D12.776.624.664.700.168 – proto-oncogene proteins c-akt MeSH D12.776.624.664.700.169 – proto-oncogene proteins c-bcl-2 MeSH D12.776.624.664.700.170 – proto-oncogene proteins c-bcl-6 MeSH D12.776.624.664.700.171 – proto-oncogene proteins c-bcr MeSH D12.776.624.664.700.172 – proto-oncogene proteins c-cbl MeSH D12.776.624.664.700.174 – proto-oncogene proteins c-crk MeSH D12.776.624.664.700.175 – proto-oncogene proteins c-ets MeSH D12.776.624.664.700.175.100 – proto-oncogene protein c-ets-1 MeSH D12.776.624.664.700.175.200 – proto-oncogene protein c-ets-2 MeSH D12.776.624.664.700.175.400 – proto-oncogene protein c-fli-1 MeSH D12.776.624.664.700.175.600 – ternary complex factors MeSH D12.776.624.664.700.175.600.100 – ets-domain protein elk-1 MeSH D12.776.624.664.700.175.600.300 – ets-domain protein elk-4 MeSH D12.776.624.664.700.177 – proto-oncogene proteins c-fes MeSH D12.776.624.664.700.179 – proto-oncogene proteins c-fos MeSH D12.776.624.664.700.180 – proto-oncogene proteins c-fyn MeSH D12.776.624.664.700.181 – proto-oncogene proteins c-hck MeSH D12.776.624.664.700.182 – proto-oncogene proteins c-jun MeSH D12.776.624.664.700.183 – proto-oncogene proteins c-kit MeSH D12.776.624.664.700.184 – proto-oncogene proteins c-maf MeSH D12.776.624.664.700.185 – proto-oncogene proteins c-mdm2 MeSH D12.776.624.664.700.186 – proto-oncogene proteins c-met MeSH D12.776.624.664.700.187 – proto-oncogene proteins c-mos MeSH D12.776.624.664.700.188 – proto-oncogene proteins c-myb MeSH D12.776.624.664.700.189 – proto-oncogene proteins c-myc MeSH D12.776.624.664.700.191 – proto-oncogene proteins c-pim-1 MeSH D12.776.624.664.700.192 – proto-oncogene proteins c-rel MeSH D12.776.624.664.700.194 – proto-oncogene proteins c-ret MeSH D12.776.624.664.700.195 – proto-oncogene proteins c-sis MeSH D12.776.624.664.700.198 – proto-oncogene proteins c-vav MeSH D12.776.624.664.700.199 – proto-oncogene proteins c-yes MeSH D12.776.624.664.700.200 – proto-oncogene proteins p21(ras) MeSH D12.776.624.664.700.202 – proto-oncogene proteins pp60(c-src) MeSH D12.776.624.664.700.204 – raf kinases MeSH D12.776.624.664.700.204.200 – proto-oncogene proteins b-raf MeSH D12.776.624.664.700.204.500 – proto-oncogene proteins c-raf MeSH D12.776.624.664.700.205 – RNA-binding protein EWS MeSH D12.776.624.664.700.250 – lymphocyte specific protein tyrosine kinase p56(lck) MeSH D12.776.624.664.700.642 – receptor, erbb-2 MeSH D12.776.624.664.700.790 – receptor, erbb-3 MeSH D12.776.624.664.700.800 – receptor, macrophage colony-stimulating factor MeSH D12.776.624.664.700.830 – receptors, thyroid hormone MeSH D12.776.624.664.700.830.500 – thyroid hormone receptors alpha MeSH D12.776.624.664.700.830.750 – thyroid hormone receptors beta MeSH D12.776.624.664.700.915 – RNA-binding protein FUS MeSH D12.776.624.664.700.957 – stathmin MeSH D12.776.624.664.700.967 – wnt1 protein MeSH D12.776.624.664.700.978 – wnt2 protein
=== Fentanyl analogs === Fentanyl analogs are types of fentanyl with various chemical modifications on any number of positions of the molecule, but still maintain, or even exceed, its pharmacological effects. Many fentanyl analogs are termed "designer drugs" because they are synthesized solely to be used illicitly. Carfentanil, a fentanyl analog, has an additional methyl ester group attached to the 4 position. Carfentanil is 20–30 times as potent as fentanyl and is common in the illicit drug chain. The drug is commonly used to tranquilize elephants and other large animals.
The argument for keeping the term "atomic weight" was primarily that it was a well understood term to those in the field, that the term "atomic mass" was already in use (as it is currently defined) and that the term "relative atomic mass" might be easily confused with relative isotopic mass (the mass of a single atom of a given nuclide, expressed dimensionlessly relative to 1/12 of the mass of carbon-12; see section above). In 1979, as a compromise, the term "relative atomic mass" was introduced as a secondary synonym for atomic weight. Twenty years later the primacy of these synonyms was reversed, and the term "relative atomic mass" is now the preferred term. However, the term "standard atomic weights" (referring to the standardized expectation atomic weights of differing samples) has not been changed, because simple replacement of "atomic weight" with "relative atomic mass" would have resulted in the term "standard relative atomic mass".
Sources: en.wikipedia.org
There was considerable media commentary about this sculpture before, during, and after the trial. The court case was also the subject of a one-hour British television programme. Since the trial, writers such as John A. Walker and Eduardo Kac have continued to reflect on the sculpture and its social implications.
Idrees Kahloon, "Border Control: The economics of immigration vs. the politics of immigration", The New Yorker, 12 June 2023, pp. 65–69. "The limits of immigration are not set by economics but by political psychology – by backlash unconcerned with net benefits." (p. 65.) Susan Harbage Page & Inéz Valdez (17 April 2011). "Residues of Border Control", Southern Spaces James, Paul (2014). "Faces of Globalization and the Borders of States: From Asylum Seekers to Citizens". Citizenship Studies. 18 (2): 208–23. doi:10.1080/13621025.2014.886440. S2CID 144816686. Philippe Legrain (2007). Immigrants: Your Country Needs Them, Little Brown, ISBN 0-316-73248-6 Aristide Zolberg (2006). A Nation by Design: Immigration Policy in the Fashioning of America, Harvard University Press, ISBN 0-674-02218-1 Philippe Legrain (2007). Immigrants: Your Country Needs Them, Little Brown, ISBN 0-316-73248-6 Ruben Rumbaut & Walter Ewing (Spring 2007). "The Myth of Immigrant Criminality and the Paradox of Assimilation: Incarceration Rates among Native and Foreign-Born Men", The Immigration Policy Center. Bryan Balin (2008). State Immigration Legislation and Immigrant Flows: An Analysis The Johns Hopkins University Douglas S. Massey (September 2005). "Beyond the Border Buildup: Towards a New Approach to Mexico-U.S. Migration", Immigration Policy Center, the American Immigration Law Foundation IPC Special Report (November 2005). "Economic Growth & Immigration: Bridging the Demographic Divide", Immigration Policy Center, the American Immigration Law Foundation American Immigration Council (April 2014).
=== Structure Stabilization Improvements === DNA brick structures can be used to synthesize various and specific geometries that serve as tools in biological studies. Due to their nucleotide nature, they can quickly dissociate under environmental fluctuations during assembly, in the presence of low concentrations of divalent cations, and in the presence of nucleases. Various methods have been developed to protect and stabilize the DNA structures. However, such methods require the encapsulation of the nanostructure making accessing DNA strands difficult and leading to covalent crosslinking. Kim and Yi presented a stabilization method involving the synthesis of DNA brick nanostructure with dendritic oligonucleotides attached to the outer surface which maintain the DNA accessibility and prevent nuclease digestion. Certain DNA brick motifs remain structurally stable at low divalent salt concentrations and in the presence of nucleases. They demonstrated that neither chemical protectants nor covalent base pair interlocking was necessary to maintain the DNA brick structure stability, especially structures with binding domain lengths of 13 nucleotides or longer. Likewise, coating their surfaces with dendritic oligonucleotides prevented the usage of chemical base-pair interlocking techniques and encapsulation methods as they could still display structural stability in cellular media and made it possible to access the DNA sequences at the surface.
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.